The ongoing Ebola outbreak in the Democratic Republic of Congo (DRC) has prompted Médecins Sans Frontières (MSF) to remind the public that the use of the ERVEBO vaccine as part of the BRAVO study does not constitute a solution to end the epidemic. The study, launched on September 19, 2026, in Bunia, Ituri, aims to evaluate the use of ERVEBO among frontline workers in Ituri and North Kivu.
ERVEBO is approved against the Ebola Zaire virus but not against the Bundibugyo virus, which is responsible for the current epidemic. However, preliminary data suggest that it may offer some degree of protection against this virus. The study seeks to document and scientifically evaluate this potential protection. As such, vaccination is considered a complementary protective measure for personnel particularly exposed to the virus.
MSF stresses that vaccination does not replace the recommended infection prevention and control measures in the response. Frontline workers must continue to use protective equipment, adhere to safe care procedures, and rapidly report any symptoms. The BRAVO study plans to target 20,000 frontline workers in Ituri and North Kivu over nine to twelve months, with three months dedicated to vaccination and at least six months of participant follow-up.
Several vaccines specifically developed against the Bundibugyo virus are currently under development and may become available in the coming months. In the meantime, ERVEBO is being studied as a transitional measure to determine if it can provide additional protection to those most exposed. MSF emphasizes that participation in the study and vaccine administration are based exclusively on voluntarism.
The ongoing epidemic in the DRC requires a comprehensive response. MSF's efforts, in collaboration with local health authorities, focus on containing the outbreak while ensuring the safety and well-being of affected communities. The situation remains closely monitored, with response strategies adjusted as necessary to address the evolving situation.
The DRC has experience in responding to Ebola outbreaks, and various organizations, including MSF, continue to support the response efforts. The use of ERVEBO, alongside other preventive measures, is part of a broader strategy to control the epidemic. International support and coordination are crucial in addressing the complex challenges posed by the outbreak.
As the situation continues to unfold, health authorities and response teams are working tirelessly to bring the epidemic under control. The response efforts involve not only medical interventions but also community engagement and support to mitigate the impact of the outbreak on local populations.
Key points
- MSF emphasizes that ERVEBO does not replace recommended prevention measures against the Bundibugyo virus.
- The BRAVO study aims to evaluate ERVEBO's potential protection against the Bundibugyo virus among frontline workers.
- Several vaccines against the Bundibugyo virus are under development and may become available soon.
